Dyne Therapeutics has increased its senior secured term loan facility with Hercules Capital by up to $125 million, adding $50 million immediately and potential additional tranches based on milestones. This expanded debt facility strengthens Dyne's financial position as it advances clinical programs for neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The funding supports upcoming clinical and regulatory milestones and prepares the company for potential U.S. commercial launches within the next two years. Hercules Capital expressed confidence in Dyne's programs and commitment to support its growth during this critical development phase.
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
